CSI Market
Sign In | Register

Lyell Immunopharma Inc (LYEL) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access LYEL Annual Balance Sheets →
Changes in quarterly balance sheet trends offer perspective on how Lyell Immunopharma Inc balances growth, leverage, and shareholder equity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/LYEL/balance-sheets
https://api.csimarket.com/api/v1/companies/LYEL/fundamentals
https://api.csimarket.com/api/v1/companies/LYEL/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Balance Sheet API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2026)
(Jun 30 2026) (Mar 31 2026) (Dec 31 2025) (Sep 30 2025)
Assets
Cash & cash equivalent92.05
Marketable Securities, Current SH85.05
Cash & Short-term Investments177.00
Other Current Assets0.00
Prepaid Expense And Other Assets Current9.11
Total Current Assets186.21
Equipment/Property/Plant Net28.53
Long-term investments19.00
Other Assets, Noncurrent40.11
Restricted Cash Noncurrent1.59
Operating Lease Right Of Use Asset17.83
Total Assets273.85
Liabilities
Accounts Payable, Current AC4.04
Accrued Liabilities And Other Liabilities42.24
Total Current Liabilities46.27
Total Long-term Debt0.00
Other liabilities, Noncurrent34.86
Asset Acquisition Contingent Consideration Liability Current-
Operating Lease Liability Noncurrent39.49
Total Liabilities81.13
Stockholders' Equity
Common Stock Value0.00
Additional Paid In Capital Common Stock1,926.99
Retained Earnings / Accumulated Deficit-1,733.99
Accumulated Other Comprehensive Income-0.28
Other Equity-0.28
Common Stockholder's Equity192.72
Total Stockholder's Equity192.72
Liabilities & Stockholder's Equity273.85
4 historic quarters locked

Sign in to unlock the full Lyell Immunopharma Inc balance sheet history.

Sign In Create Free Account

About Lyell Immunopharma Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001628280-26-070171

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API Connect Your AI